Literature DB >> 1554833

Invasive infections due to Candida krusei: report of ten cases of fungemia that include three cases of endophthalmitis.

D P McQuillen1, B S Zingman, F Meunier, S M Levitz.   

Abstract

Candida krusei has become an increasingly important invasive pathogen, particularly in immunocompromised patients. Previous experimental and clinical experience suggest that C. krusei has a low propensity for hematogenously infecting the eye. We report 10 cases of fungemia due to C. krusei at our institutions, including three cases of endophthalmitis due to C. krusei. Fungemia was associated with nodular skin lesions in all seven patients with neutropenia and occurred despite administration of antifungal prophylaxis or empirical therapy. None of the patients apparently died as a direct result of C. krusei fungemia. Treatment with amphotericin B resulted in resolution of endophthalmitis, although one patient required vitrectomy. Early institution of aggressive therapy with amphotericin B may alter the course and improve the prognosis of C. krusei infection, particularly in immunocompromised patients.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1554833     DOI: 10.1093/clinids/14.2.472

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  18 in total

Review 1.  Antifungal prophylaxis during neutropenia and immunodeficiency.

Authors:  O Lortholary; B Dupont
Journal:  Clin Microbiol Rev       Date:  1997-07       Impact factor: 26.132

2.  Successful treatment of catheter-associated fungemia due to Candida krusei and Trichosporon beigelii in a leukemic patient receiving prophylactic itraconazole.

Authors:  S Spánik; T Kollár; J Gyarfás; A Kunová; V Krcméry
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-02       Impact factor: 3.267

Review 3.  Susceptibility testing of fungi: current status of the standardization process.

Authors:  J N Galgiani
Journal:  Antimicrob Agents Chemother       Date:  1993-12       Impact factor: 5.191

4.  Strain variation among and antifungal susceptibilities of isolates of Candida krusei.

Authors:  Y F Berrouane; R J Hollis; M A Pfaller
Journal:  J Clin Microbiol       Date:  1996-07       Impact factor: 5.948

5.  Species-specific identification of Candida krusei by hybridization with the CkF1,2 DNA probe.

Authors:  A Carlotti; A Couble; J Domingo; K Miroy; J Villard
Journal:  J Clin Microbiol       Date:  1996-07       Impact factor: 5.948

6.  Rapid identification and fingerprinting of Candida krusei by PCR-based amplification of the species-specific repetitive polymorphic sequence CKRS-1.

Authors:  A Carlotti; F Chaib; A Couble; N Bourgeois; V Blanchard; J Villard
Journal:  J Clin Microbiol       Date:  1997-06       Impact factor: 5.948

Review 7.  Clinical and laboratory diagnosis of invasive candida infection in neutropenic patients.

Authors:  M Kalin; B Petrini
Journal:  Med Oncol       Date:  1996-12       Impact factor: 3.064

8.  Experimental hematogenous candidiasis caused by Candida krusei and Candida albicans: species differences in pathogenicity.

Authors:  E Anaissie; R Hachem; C K-Tin-U; L C Stephens; G P Bodey
Journal:  Infect Immun       Date:  1993-04       Impact factor: 3.441

9.  In vitro studies of a new antifungal triazole, D0870, against Candida albicans, Cryptococcus neoformans, and other pathogenic yeasts.

Authors:  T Peng; J N Galgiani
Journal:  Antimicrob Agents Chemother       Date:  1993-10       Impact factor: 5.191

10.  Typing of Candida krusei clinical isolates by restriction endonuclease analysis and hybridization with CkF1,2 DNA probe.

Authors:  A Carlotti; R Grillot; A Couble; J Villard
Journal:  J Clin Microbiol       Date:  1994-07       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.